Czibere Akos, serving as the Chief Medical Officer for Aktis Oncology, Inc. (NASDAQ: AKTS), executed a series of stock transactions on July 8, 2026, resulting in the sale of 50,000 shares of the company's common stock. The aggregate value of these sales was approximately $1.39 million. These divestments occurred on the same day that Mr. Akos exercised stock options, a sequence of events that fundamentally altered his direct equity position within the firm.
The execution of the sales took place across multiple transactions at varying price points. Specifically, 14,800 shares were sold at prices ranging from $26.52 to $27.51 per share. A larger block of 30,829 shares was sold at prices between $27.53 and $28.50 per share. The remaining 4,371 shares were sold in a price range of $28.63 to $28.74 per share. The stock currently trades at $28.42, representing a decline of approximately 17% from its 52-week high of $34.19. Despite this recent pullback, the stock has gained 27% over the past six months. According to InvestingPro analysis, the stock appears overvalued at current levels. An InvestingPro Tip notes the stock has taken a big hit over the last week, with 12 additional tips available to subscribers.
Prior to these sales, Mr. Akos acquired 50,000 shares of Aktis Oncology common stock by exercising stock options at a price of $4.95 per share, totaling $247,500. The options exercised had a vesting schedule that began with 25% of the original shares vesting on July 1, 2025, with the remainder vesting in monthly installments thereafter. Following these transactions, Mr. Akos directly holds no shares of Aktis Oncology common stock. He retains 221,218 derivative shares in the form of stock options.
In other recent news, Aktis Oncology has initiated a Phase 1b clinical trial of AKY-2519 for patients with metastatic castration-resistant prostate cancer. This trial will involve multiple prostate-specific radioligand therapy centers across the United States, targeting both PLUVICTO-naïve and PLUVICTO-experienced cohorts. The study aims to explore three dose levels in each cohort, with preliminary results anticipated in 2027. Additionally, Aktis Oncology announced the appointment of Glenn Gormley, MD, PhD, to its board of directors. Dr. Gormley will serve as an independent director and co-chair of the newly established Science and Technology Committee. He brings over 30 years of experience in biopharmaceutical research and development, having previously held senior positions at Daiichi Sankyo Co., Ltd. His expertise includes overseeing the development of a diversified pipeline and leading global R&D strategies. These developments reflect Aktis Oncology’s ongoing efforts in expanding its leadership and advancing its clinical programs.